This company has been marked as potentially delisted and may not be actively trading. Immuron (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrendsBuy This Stock IMRN vs. RNTX, CNTB, ATHE, BDRX, ELYM, QNTM, ITRM, AKTX, BRNS, and ACRVShould you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Rein Therapeutics (RNTX), Connect Biopharma (CNTB), Alterity Therapeutics (ATHE), Biodexa Pharmaceuticals (BDRX), Eliem Therapeutics (ELYM), Quantum Biopharma (QNTM), Iterum Therapeutics (ITRM), Akari Therapeutics (AKTX), Barinthus Biotherapeutics (BRNS), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical preparations" industry. Immuron vs. Its Competitors Rein Therapeutics Connect Biopharma Alterity Therapeutics Biodexa Pharmaceuticals Eliem Therapeutics Quantum Biopharma Iterum Therapeutics Akari Therapeutics Barinthus Biotherapeutics Acrivon Therapeutics Rein Therapeutics (NASDAQ:RNTX) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk. Do institutionals & insiders hold more shares of RNTX or IMRN? 90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, RNTX or IMRN? Rein Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Immuron has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Does the media favor RNTX or IMRN? In the previous week, Rein Therapeutics and Rein Therapeutics both had 3 articles in the media. Rein Therapeutics' average media sentiment score of 0.30 beat Immuron's score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Immuron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in RNTX or IMRN? Immuron received 188 more outperform votes than Rein Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRein TherapeuticsN/AN/AImmuronOutperform Votes18867.87% Underperform Votes8932.13% Do analysts rate RNTX or IMRN? Immuron has a consensus target price of $5.00, indicating a potential upside of 185.71%. Given Immuron's stronger consensus rating and higher probable upside, analysts clearly believe Immuron is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immuron 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, RNTX or IMRN? Immuron has higher revenue and earnings than Rein Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$15.73M-$2.86-0.66Immuron$3.21M3.18-$4.55MN/AN/A Is RNTX or IMRN more profitable? Immuron's return on equity of 0.00% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -74.08% -27.93% Immuron N/A N/A N/A SummaryImmuron beats Rein Therapeutics on 10 of the 12 factors compared between the two stocks. Get Immuron News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricImmuronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.03M$6.87B$5.57B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E RatioN/A8.4326.6319.64Price / Sales3.18262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book1.206.536.964.60Net Income-$4.55M$143.25M$3.23B$248.06M Immuron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNImmuron1.3355 of 5 stars$1.75-12.5%$5.00+185.7%-21.9%$11.03M$3.21M0.00N/AShort Interest ↑RNTXRein TherapeuticsN/A$1.98-1.0%N/AN/A$43.87MN/A-0.639News CoverageCNTBConnect Biopharma3.3403 of 5 stars$0.78-1.3%$8.00+924.3%-43.5%$43.39M$26.03M0.00110News CoverageAnalyst ForecastATHEAlterity Therapeutics2.1219 of 5 stars$4.84+2.3%$12.00+147.9%+132.8%$42.92MN/A0.0010BDRXBiodexa Pharmaceuticals0.4788 of 5 stars$1.15flatN/AN/A$42.03M$83K0.0020Short Interest ↑ELYMEliem TherapeuticsN/A$1.39+12.1%N/A-85.3%$41.36MN/A-2.629High Trading VolumeQNTMQuantum BiopharmaN/A$15.21-1.6%N/AN/A$41.16MN/A-0.99N/APositive NewsGap UpITRMIterum Therapeutics2.423 of 5 stars$1.02+5.2%$9.00+782.4%-15.3%$40.80MN/A-0.7810Analyst RevisionGap DownAKTXAkari TherapeuticsN/A$1.25+1.5%N/A-61.0%$40.22MN/A0.009Positive NewsBRNSBarinthus Biotherapeutics2.827 of 5 stars$0.99-0.5%$5.17+421.7%-52.7%$40.14M$14.97M-0.66107Gap UpACRVAcrivon Therapeutics4.1258 of 5 stars$1.28-5.2%$17.71+1,283.9%-84.5%$40.13MN/A-0.4758News CoverageAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies RNTX Competitors CNTB Competitors ATHE Competitors BDRX Competitors ELYM Competitors QNTM Competitors ITRM Competitors AKTX Competitors BRNS Competitors ACRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRN) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
